WASHINGTON — The Food and Drug Administration formally authorized a second vaccine for emergency use from Moderna. The biotech upstart won authorization for use in adults following extensive federal analysis of the vaccine, which the FDA found to be 94% effective at preventing the disease.
“With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” said FDA Commissioner Dr. Stephen Hahn in a statement.
The FDA decision represents another leap forward in the effort to combat the coronavirus, which has already killed more than 300,000 people in the U.S. alone. Since the Pfizer vaccine’s authorization last week, health and defense officials have launched a vast effort to distribute millions of doses across the country. Health care workers and older adults were first in line for the inoculations when providers began administering them Monday.
Today marks another significant step in our nation’s response to COVID-19 that will allow for more Americans to receive a vaccine in the coming months under the direction of the Centers for Disease Control and Prevention (CDC), states and public health experts. HDA appreciates the tireless work of our manufacturer trading partners, FDA, CDC and Operation Warp Speed to advance two vaccine candidates so quickly,” said Healthcare Distribution Alliance (HDA) president and CEO Chester “Chip” Davis
“Each part of the healthcare system — in close coordination with federal and state governments — has a role to play in this massive logistics undertaking. HDA is pleased that the federal government has recognized and is relying on the expertise of our healthcare distributor members in ensuring vaccines, the essential supplies needed to administer them, and other COVID-19 related treatments and therapeutics are delivered safely and efficiently to provider points of administration. This spirit of public- and private-sector collaboration will not only be important in bringing an end to the COVID-19 pandemic, but also enhancing our resiliency for future public health crises,” Davis added.